Demystifying Bispecific Antibodies for Hematologic Malignancies
Since the U.S. Food and Drug Administration’s (FDA’s) initial approval of the anti-CD20 antibody rituximab in 1997 to treat relapsed or refractory low-grade B...
Demystifying Proteomics in Hematology
The central dogma of molecular biology describes the flow of information in a cell, from the DNA in a gene to RNA to protein....
Demystifying Genetic Testing for Bleeding Disorders
When hemophilia and von Willebrand disease (vWD) were first recognized, doctors didn’t diagnose a patient until he (or, much more infrequently, she) experienced a...
Demystifying Multicolor Flow Cytometry
Flow cytometry has come a long way in the 80 years since its inception. The now highly sophisticated technique is an indispensable tool for...
Demystifying Epigenetics in Hematology
In the early 20th century, German researcher Theodor Boveri described the basic tenets of tumor biology: Cells can turn cancerous when they lose the...
Demystifying Liquid Biopsies
Tumor biopsies have long been the standard method for diagnosing, monitoring, and treating cancer and, in the era of precision medicine, molecular analyses of...
Demystifying Zebrafish
Despite the vast sequencing data available to study the genetics of human disease, experimental animal models still play a critical role in unraveling the...
Demystifying Gene Editing With CRISPR
Gene editing has received a great deal of media attention in recently due to its potential for advancing science and treating disease. In a...
Demystifying Genomic Panels for Hematologic Malignancies
It seems as if every medical journal, and even President Obama’s “State of the Union” address earlier this year, mentions “precision” medicine, “targeted” therapies,...
Current Issue
December 2019, Volume 5, Issue 15
This issue examines the hidden costs of participating in clinical trials, explores the pediatric hematology/oncology workforce, and more.
